TY - JOUR
T1 - Association of cystatin C with left ventricular structure and function
T2 - The Dallas Heart Study
AU - Patel, Parag C.
AU - Ayers, Colby R.
AU - Murphy, Sabina A.
AU - Peshock, Ronald
AU - Khera, Amit
AU - De Lemos, James A.
AU - Balko, Jody A.
AU - Gupta, Sachin
AU - Mammen, Pradeep P.A.
AU - Drazner, Mark H.
AU - Markham, David W.
N1 - Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.
PY - 2009/3
Y1 - 2009/3
N2 - Background-Cystatin C, a novel marker of renal function, has been associated with heart failure and cardiovascular mortality in older individuals. We tested the hypothesis that cystatin C is associated with preclinical cardiac structural and functional abnormalities in a younger population-based sample. Methods and Results-The study included participants in the Dallas Heart Study (ages 30 to 65 years) who had measurements of cystatin C and cardiac MRI. The associations of cystatin C with left ventricular (LV) mass, LV end-systolic and -diastolic volumes, concentricity (LV mass/LV end-diastolic volume), LV wall thickness, and LV ejection fraction were evaluated. Cystatin C levels ranged from 0.46 to 6.55 mg/L. In univariable analyses, increasing levels of cystatin C correlated with higher LV mass, concentricity, and wall thickness (P<0.001), but not with LV end-systolic volume, LV end-diastolic volume, or LV ejection fraction. After adjustment with traditional covariates and estimated glomerular filtration rate by the modification of diet in renal disease formula, log-transformed cystatin C remained independently associated with LV mass (P<0.001), concentricity (P=0.027), and wall thickness (P<0.001). These associations persisted when creatinine or estimated glomerular filtration rate by the Cockcroft-Gault formula were included in the models. Conclusions-Higher levels of cystatin C were associated with increased LV mass and a concentric LV hypertrophy phenotype. These findings were independent of potential confounding variables including standard measurements of renal function, supporting the hypothesis that cystatin C may be useful to identify individuals with preclinical structural heart abnormalities.
AB - Background-Cystatin C, a novel marker of renal function, has been associated with heart failure and cardiovascular mortality in older individuals. We tested the hypothesis that cystatin C is associated with preclinical cardiac structural and functional abnormalities in a younger population-based sample. Methods and Results-The study included participants in the Dallas Heart Study (ages 30 to 65 years) who had measurements of cystatin C and cardiac MRI. The associations of cystatin C with left ventricular (LV) mass, LV end-systolic and -diastolic volumes, concentricity (LV mass/LV end-diastolic volume), LV wall thickness, and LV ejection fraction were evaluated. Cystatin C levels ranged from 0.46 to 6.55 mg/L. In univariable analyses, increasing levels of cystatin C correlated with higher LV mass, concentricity, and wall thickness (P<0.001), but not with LV end-systolic volume, LV end-diastolic volume, or LV ejection fraction. After adjustment with traditional covariates and estimated glomerular filtration rate by the modification of diet in renal disease formula, log-transformed cystatin C remained independently associated with LV mass (P<0.001), concentricity (P=0.027), and wall thickness (P<0.001). These associations persisted when creatinine or estimated glomerular filtration rate by the Cockcroft-Gault formula were included in the models. Conclusions-Higher levels of cystatin C were associated with increased LV mass and a concentric LV hypertrophy phenotype. These findings were independent of potential confounding variables including standard measurements of renal function, supporting the hypothesis that cystatin C may be useful to identify individuals with preclinical structural heart abnormalities.
KW - Concentricity
KW - Cystatin C
KW - Dallas Heart Study
KW - Hypertension
KW - Left ventricular hypertrophy
KW - Rrenal function
UR - http://www.scopus.com/inward/record.url?scp=67650624206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=67650624206&partnerID=8YFLogxK
U2 - 10.1161/CIRCHEARTFAILURE.108.807271
DO - 10.1161/CIRCHEARTFAILURE.108.807271
M3 - Article
C2 - 19808324
AN - SCOPUS:67650624206
SN - 1941-3289
VL - 2
SP - 98
EP - 104
JO - Circulation: Heart Failure
JF - Circulation: Heart Failure
IS - 2
ER -